Polo-like Kinase 4 is Associated with Advanced TNM Stages and Reduced Survival and Its Inhibition Improves Chemosensitivity in Colorectal Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2022 Jul 5

PMID 35782899

Authors

Zhengang Duan

Lei Cai

Jin Cao

Wei Wu

Affiliations

Soon will be listed here.

Abstract

High expression of polo-like kinase 4 (PLK4) promotes tumorigenesis and is correlated with poor prognosis in several kinds of cancer. However, the prognostic value of PLK4 in colorectal cancer (CRC) has not been elucidated. The aim of the present study was to investigate the association between PLK4 and the prognosis and effect of PLK4 inhibition on chemosensitivity in CRC. A total of 142 patients with CRC were enrolled, and 142 pairs of CRC and para-carcinoma tissues were used to measure PLK4 protein expression using immunohistochemistry (IHC). Among them, 69 pairs were used to detect PLK4 mRNA expression using reverse transcription-quantitative PCR. In addition, PLK4-small interfering RNA (siRNA) was transfected into CRC cells, followed by 5-fluorouracil (5-FU) treatment for it was a fundamental chemotherapy for CRC. In addition, western blotting was used to detect PLK4 protein expression among human colonic epithelial cell and human CRC cell lines, including HCT-116, LoVo, SW480 and HT-29, as well as nuclear translocation of β-catenin. The IHC score and mRNA expression of PLK4 were higher in CRC tissues compared with para-carcinoma tissues (both P<0.001). Furthermore, the IHC score of tumor PLK4 was not correlated with pathological grade (P=0.585), T stage (P=0.357), N stage (P=0.107225) or tumor-node-metastasis (TNM) stage (P=0.093). The mRNA expression of tumor PLK4 was positively correlated with N stage (P=0.019) and TNM stage (P=0.004), but not with pathological grade (P=0.498) or T stage (P=0.112). Of note, the high protein expression of tumor PLK4 was an independent factor for poor overall survival (OS; P=0.048). In addition, PLK4 was elevated in CRC cell lines; PLK4-siRNA reduced the 50% inhibitory concentration value of 5-FU in HCT-116 (4.4±0.1 µM vs. 7.6±1.4 µM) and LoVo cells (5.5±0.6 µM vs. 9.9±1.8 µM) (both P<0.05). Besides, PLK4-siRNA decreased nuclear translocation of β-catenin. In conclusion, the high expression of tumor PLK4 was associated with advanced TNM stage and shorter OS in patients with CRC. In addition, targeting PLK4 improved chemosensitivity in CRC cells.

Citing Articles

Tumor polo-like kinase 4 protein expression reflects lymphovascular invasion, higher Federation of Gynecology and Obstetrics stage, and shortened survival in endometrial cancer patients who undergo surgical resection.

Zhao Q, Wang M, Chen M BMC Womens Health. 2024; 24(1):101.

PMID: 38326803 PMC: 10851612. DOI: 10.1186/s12905-024-02911-9.

References

Li Z, Dai K, Wang C, Song Y, Gu F, Liu F . Expression of Polo-Like Kinase 4(PLK4) in Breast Cancer and Its Response to Taxane-Based Neoadjuvant Chemotherapy. J Cancer. 2016; 7(9):1125-32. PMC: 4911880. DOI: 10.7150/jca.14307. View

Zhang X, Wei C, Liang H, Han L . Polo-Like Kinase 4's Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy. Front Oncol. 2021; 11:587554. PMC: 7994899. DOI: 10.3389/fonc.2021.587554. View

Li J, Mo R, Zheng L . MicroRNA-490-3p inhibits migration and chemoresistance of colorectal cancer cells via targeting TNKS2. World J Surg Oncol. 2021; 19(1):117. PMC: 8045283. DOI: 10.1186/s12957-021-02226-1. View

Zhang N, Liu F, Ma T, Zhang Z . LncRNA SNHG1 contributes to tumorigenesis and mechanism by targeting miR-338-3p to regulate PLK4 in human neuroblastoma. Eur Rev Med Pharmacol Sci. 2019; 23(20):8971-8983. DOI: 10.26355/eurrev_201910_19296. View

Kim D, Ahn J, Han H, Kim H, Hwang J, Lee K . Cep131 overexpression promotes centrosome amplification and colon cancer progression by regulating Plk4 stability. Cell Death Dis. 2019; 10(8):570. PMC: 6662699. DOI: 10.1038/s41419-019-1778-8. View

Nozawa H, Sonoda H, Ishii H, Emoto S, Murono K, Kaneko M . Postoperative chemotherapy is associated with prognosis of stage IV colorectal cancer treated with preoperative chemotherapy/chemoradiotherapy and curative resection. Int J Colorectal Dis. 2019; 35(1):177-180. DOI: 10.1007/s00384-019-03461-5. View

Jin M, Frankel W . Lymph Node Metastasis in Colorectal Cancer. Surg Oncol Clin N Am. 2018; 27(2):401-412. DOI: 10.1016/j.soc.2017.11.011. View

Arnold M, Sierra M, Laversanne M, Soerjomataram I, Jemal A, Bray F . Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2016; 66(4):683-691. DOI: 10.1136/gutjnl-2015-310912. View

Marina M, Saavedra H . Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance. Front Biosci (Landmark Ed). 2014; 19(2):352-65. PMC: 3999971. DOI: 10.2741/4212. View

10.

Zhang Z, Wang Z, Huang K, Liu Y, Wei C, Zhou J . PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma. Cancer Lett. 2018; 443:91-107. DOI: 10.1016/j.canlet.2018.11.034. View

11.

Ijsselsteijn R, Jansen J, de Wind N . DNA mismatch repair-dependent DNA damage responses and cancer. DNA Repair (Amst). 2020; 93:102923. DOI: 10.1016/j.dnarep.2020.102923. View

12.

Kazazian K, Go C, Wu H, Brashavitskaya O, Xu R, Dennis J . Plk4 Promotes Cancer Invasion and Metastasis through Arp2/3 Complex Regulation of the Actin Cytoskeleton. Cancer Res. 2016; 77(2):434-447. DOI: 10.1158/0008-5472.CAN-16-2060. View

13.

Liu X . Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment. Transl Oncol. 2015; 8(3):185-95. PMC: 4486469. DOI: 10.1016/j.tranon.2015.03.010. View

14.

Godinho S, Picone R, Burute M, Dagher R, Su Y, Leung C . Oncogene-like induction of cellular invasion from centrosome amplification. Nature. 2014; 510(7503):167-71. PMC: 4061398. DOI: 10.1038/nature13277. View

15.

Bao J, Yu Y, Chen J, He Y, Chen X, Ren Z . MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway. Cell Death Dis. 2018; 9(10):1045. PMC: 6185973. DOI: 10.1038/s41419-018-1020-0. View

16.

Zhao Y, Wang X . PLK4: a promising target for cancer therapy. J Cancer Res Clin Oncol. 2019; 145(10):2413-2422. DOI: 10.1007/s00432-019-02994-0. View

17.

Pu J, Hu Z, Zhang D, Zhang T, He K, Dai T . MiR-654-3p Suppresses Non-Small Cell Lung Cancer Tumourigenesis by Inhibiting PLK4. Onco Targets Ther. 2020; 13:7997-8008. PMC: 7431606. DOI: 10.2147/OTT.S258616. View

18.

Hu Z, Gu X, Zhong R, Zhong H . Tumor-infiltrating CD45RO memory cells correlate with favorable prognosis in patients with lung adenocarcinoma. J Thorac Dis. 2018; 10(4):2089-2099. PMC: 5949455. DOI: 10.21037/jtd.2018.03.148. View

19.

Meng L, Zhou Y, Ju S, Han J, Song C, Kong J . A cis-eQTL genetic variant in PLK4 confers high risk of hepatocellular carcinoma. Cancer Med. 2019; 8(14):6476-6484. PMC: 6797585. DOI: 10.1002/cam4.2487. View

20.

Wang G, Wang Z, Jin Z . Application and Progress of Texture Analysis in the Therapeutic Effect Prediction and Prognosis of Neoadjuvant Chemoradiotherapy for Colorectal Cancer. Chin Med Sci J. 2019; 34(1):45-50. DOI: 10.24920/003572. View